Intellia Therapeutics (NASDAQ:NTLA) Rating Reiterated by Wedbush

Intellia Therapeutics (NASDAQ:NTLA)‘s stock had its “neutral” rating reaffirmed by research analysts at Wedbush in a research report issued on Tuesday, Benzinga reports. They presently have a $29.00 price objective on the stock. Wedbush’s price objective suggests a potential upside of 36.99% from the stock’s previous close.

NTLA has been the topic of a number of other reports. Wolfe Research initiated coverage on Intellia Therapeutics in a report on Thursday, February 15th. They set a “peer perform” rating on the stock. Canaccord Genuity Group increased their price target on shares of Intellia Therapeutics from $72.00 to $73.00 and gave the company a “buy” rating in a research report on Friday, February 23rd. Finally, The Goldman Sachs Group lowered shares of Intellia Therapeutics from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $136.00 to $32.00 in a research report on Friday, February 23rd. One research analyst has rated the stock with a sell rating, four have issued a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $67.00.

Intellia Therapeutics Stock Performance

Shares of NTLA opened at $21.17 on Tuesday. The stock has a fifty day moving average of $26.81 and a 200-day moving average of $27.68. Intellia Therapeutics has a 52 week low of $20.78 and a 52 week high of $47.48. The stock has a market capitalization of $2.04 billion, a price-to-earnings ratio of -3.91 and a beta of 1.77.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, February 22nd. The company reported ($1.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.01. Intellia Therapeutics had a negative return on equity of 43.91% and a negative net margin of 893.34%. The business had revenue of ($1.92) million during the quarter, compared to the consensus estimate of $15.10 million. During the same period in the previous year, the company posted ($1.40) earnings per share. As a group, equities analysts forecast that Intellia Therapeutics will post -5.58 EPS for the current year.

Insider Activity at Intellia Therapeutics

In other Intellia Therapeutics news, EVP James Basta sold 2,297 shares of the firm’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $32.99, for a total value of $75,778.03. Following the completion of the transaction, the executive vice president now owns 81,571 shares in the company, valued at approximately $2,691,027.29. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 3.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Blue Trust Inc. purchased a new position in Intellia Therapeutics during the fourth quarter worth about $26,000. Signaturefd LLC boosted its position in shares of Intellia Therapeutics by 89.3% during the 4th quarter. Signaturefd LLC now owns 1,592 shares of the company’s stock valued at $49,000 after acquiring an additional 751 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Intellia Therapeutics by 95.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 2,263 shares of the company’s stock worth $72,000 after purchasing an additional 1,108 shares in the last quarter. Daiwa Securities Group Inc. increased its position in shares of Intellia Therapeutics by 35.0% in the fourth quarter. Daiwa Securities Group Inc. now owns 3,056 shares of the company’s stock worth $93,000 after purchasing an additional 793 shares during the last quarter. Finally, Spire Wealth Management raised its stake in Intellia Therapeutics by 3,789.0% in the fourth quarter. Spire Wealth Management now owns 3,889 shares of the company’s stock valued at $119,000 after purchasing an additional 3,789 shares in the last quarter. 88.77% of the stock is owned by institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.